Pages that link to "Q26775817"
Jump to navigation
Jump to search
The following pages link to Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib (Q26775817):
Displaying 6 items.
- Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it. (Q39039088) (← links)
- EML4-ALK-positive lung adenocarcinoma presenting an unusual metastatic pattern in a 29-year-old woman who is alive and well in her third year follow up:A case report (Q41492859) (← links)
- Identification of EML4-ALK as an alternative fusion gene in epithelioid inflammatory myofibroblastic sarcoma (Q42181725) (← links)
- Active fraction (HS7) from Taiwanofungus camphoratus inhibits AKT-mTOR, ERK and STAT3 pathways and induces CDK inhibitors in CL1-0 human lung cancer cells (Q47101798) (← links)
- Panomics for Precision Medicine (Q47348974) (← links)
- The Case for Proteomics and Phospho-Proteomics in Personalized Cancer Medicine (Q91799734) (← links)